Last checked at 16 Sep 2008 11:45
| 16 September 2008 |
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
End of Offer Period
Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery business, announces that it is no longer actively seeking a buyer for the Company as part of the strategic review announced on 2 May 2008 and, accordingly, is no longer in an offer period.
The Company's shares remain suspended while the board considers how best to maximise value for shareholders.
- Ends-
For further information please contact:
| Sareum Holdings plc | 01223 497700 |
| Tim Mitchell, Chief Executive Officer |
|
| Buchanan Communications | 020 7466 5000 |
| Tim Anderson, Mary-Jane Johnson |
|
| Grant Thornton UK LLP | 020 7383 5100 |
| Philip Secrett, Colin Aaronson |
|
Notes for editors:
About Sareum Holdings plc
Sareum Holdings plc is a drug discovery business headquartered in Cambridge, UK. The Company was formed in August 2003 to discover new drugs for the treatment of cancer.
Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.
Sareum joined the AIM market of the London Stock Exchange in October 2004 under the symbol SAR. For further information, please visit www.sareum.co.uk